Republican Senators Call for Investigation into Abortion Pill Safety

Three Republican senators are urging Attorney General Pam Bondi to look into whether pharmaceutical companies misled the public regarding the safety and effectiveness of the abortion pill.

In a letter acquired by The Daily Signal, the senators expressed concerns about a “serious public health failure that endangers countless American women.” They are asking for an investigation into possible misinformation regarding mifepristone and its risks, suggesting it has placed numerous women in jeopardy.

Senators Steve Daines from Montana, Marsha Blackburn of Tennessee, and Jim Banks from Indiana sent this request on Tuesday, calling for a review of both criminal and civil actions concerning abortion drug manufacturers.

This demand follows a study by the Ethics and Public Policy Center, which indicated that women who take mifepristone experience serious adverse effects at rates significantly higher—22 times, in fact—than what is indicated on the FDA-approved label.

Currently, approximately two-thirds of abortions are carried out using mifepristone and misoprostol.

The senators emphasized that opinions on abortion itself should not overshadow the urgent health and safety concerns for women. They are pressing the Justice Department to initiate a prompt investigation.

Daines stated, “We strongly urge the Department of Justice to investigate the possible criminal and civil misconduct by chemical abortion manufacturers.” He pointed out the critical need for rapid action based on the data and its implications for public health, questioning whether federal laws were breached that could jeopardize women’s safety.

Notably, safety regulations for mifepristone were relaxed in 2016 and again in 2023. The senators argued that the DOJ must examine how these changes were implemented and whether proper procedures were followed.

According to the letter, there are uncertainties about whether the FDA collaborated with Danco Laboratories, the maker of Mifeprex, regarding any new data, clinical trials, or market studies that led to the easing of safety standards.

Furthermore, they believe the DOJ from President Trump’s administration should also look into the absence of reporting requirements regarding injuries linked to the abortion pill.

“Americans deserve to know the actual risks of the medications they take,” the letter asserts, questioning why the FDA would suspend reporting requirements in such serious cases.

The senators remarked that such lapses keep the public uninformed and undermine the ability to provide informed consent.

They concluded by suggesting that if this mattered more broadly, Democrats would be more vocal. However, since it pertains to abortion, they feel action is lacking. “But you, however, can take steps,” they urged Bondi.